Elite Pharmaceuticals Inc will move to a mid-stage study of its pain treatment candidate after two early stage trials proved successful. The drug candidate, an oxycodone called ELI-154, is a controlled release pain medication meant to keep the same level of the medication in the blood stream for a 24-hour period.
Elite compared the drug in the trial of 19 men with Oxycontin, made by Purdue Pharma. The study showed that where Oxycontin has valley between two 12-hour doses, that gap was absent in the ELI-154 24-hour dose. This result came during the second Phase I clinical trial, with the first being conducted to determine proof of concept.